Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Receptor tyrosine kinase (RTK); VEGF-A

Mouse and cell culture studies identified apratoxin analogs that could be useful for treating cancer. Apratoxins are cyanobacteria-derived compounds that downregulate expression of genes including RTKs. In a human colorectal cancer cell line, the analogs reduced viability and VEGF-A secretion with single-digit nanomolar to subnanomolar IC50 values. In a mouse xenograft model of human colorectal cancer, injection of an apratoxin analog caused a dose-dependent decrease in tumor growth compared with vehicle injection. Next steps could include evaluating the lead analog in additional mouse models of cancer.

SciBX 7(17); doi:10.1038/scibx.2014.486
Published online May 1, 2014

Patent and licensing status unavailable

Chen, Q.-Y. et al. J. Med. Chem.; published online March 24, 2014;
doi:10.1021/jm4019965
Contact: Hendrik Luesch, University of Florida, Gainesville, Fla.
e-mail:

luesch@cop.ufl.edu